Purpose: Paclitaxel, when combined with carboplatin, exhibits a platelet-sparing effect. Paclitaxel is formulated in Cremophor EL (CrEL), which has been shown in preclinical models to reduce haematological toxicity from radiotherapy and chemotherapy. We sought to determine the effect of a 3-h infusion of 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel) CrEL on myelosuppression following carboplatin chemotherapy, and the effect of CrEL on carboplatin pharmacokinetics.
Methods: A total of 16 patients with locally advanced or metastatic cancer were randomized to receive either CrEL or saline over 3 h prior to carboplatin (area under the curve, AUC, 5-7). Each patient was subsequently crossed over to the other treatment. Blood samples were collected at selected time-points for estimation of platinum AUC and 24-h platinum levels. Full blood counts were obtained three times per week.
Results: Of the 16 patients randomized, 15 were evaluable. Myelosuppression was measured by percentage fall at nadir and nadir levels. No significant differences were obtained when comparing CrEL and saline with respect to the above end-points after adjusting for multiple testing. There was no evidence to indicate that CrEL altered the pharmacokinetics of carboplatin.
Conclusion: CrEL at this dose and schedule does not appear to be a major contributory factor to the platelet-sparing effect of paclitaxel when combined with carboplatin, nor does it alter the pharmacokinetics of carboplatin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-004-0792-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogs.
BMC Vet Res
December 2024
Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France.
Background: Carboplatin is a human chemotherapeutic agent which is frequently used in dogs for the management of solid tumors. In human patient, its dosage is adjusted carefully, based on the creatinine clearance computation. In dogs however, the pharmacokinetics of carboplatin is poorly known and the dose 300 mg/m2 is based mostly on empirical data.
View Article and Find Full Text PDFFabrication of Biomimetic Hybrid Liposomes via Microfluidic Technology: Homotypic Targeting and Antitumor Efficacy Studies in Glioma Cells.
Int J Nanomedicine
December 2024
Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, 70125, Italy.
Introduction: The treatment of glioblastoma is hindered by the blood-brain barrier (BBB) and rapid drug clearance by the immune system. To address these challenges, we propose a novel drug delivery system using liposomes modified with cell membrane fragments. These modified liposomes can evade the immune system, cross the BBB, and accumulate in tumor tissue through homotypic targeting, thereby delivering drugs like paclitaxel and carboplatin more effectively.
View Article and Find Full Text PDFA global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data.
Eng Comput
August 2023
Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, USA.
Unlabelled: Neoadjuvant chemotherapy (NAC) is a standard-of-care treatment for locally advanced triple negative breast cancer (TNBC) before surgery. The early assessment of TNBC response to NAC would enable an oncologist to adapt the therapeutic plan of a non-responding patient, thereby improving treatment outcomes while preventing unnecessary toxicities. To this end, a promising approach consists of obtaining in silico personalized forecasts of tumor response to NAC via computer simulation of mechanistic models constrained with patient-specific magnetic resonance imaging (MRI) data acquired early during NAC.
View Article and Find Full Text PDFImpact of baseline renal impairment on severe neutropenia development in pemetrexed and carboplatin thoracic cancer treatment.
Support Care Cancer
November 2024
Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
Article Synopsis
- Carboplatin (CBDCA) and pemetrexed (PEM) are common treatments for thoracic cancer; however, renal impairment (RI) can lead to severe neutropenia, a significant side effect of these drugs.
- A study involving 155 patients found that severe neutropenia occurred in 41.2% of those with RI, compared to 20.7% in those without, highlighting the increased risk for patients with kidney issues.
- The research concluded that baseline RI is a significant risk factor for developing severe neutropenia during treatment, indicating the need for careful monitoring in these patients.
Pharmaceuticals in the environment: A strategy for prioritizing molecules of environmental concern.
Chemosphere
November 2024
Laboratory of Integrated Sciences, Universidade Federal de São Paulo, Diadema, SP, CEP 09972-270, Brazil; Department of Environmental Sciences, Laboratory of Ecology and Nature Conservancy (LECON), Group of Landscape Ecology and Conservation Planning (LEPLAN), Universidade Federal de São Paulo, Diadema, CEP 09972-270, Brazil; Antimicrobial Resistance Institute of São Paulo (ARIES), São Paulo, Brazil. Electronic address:
Article Synopsis
- * The proposed strategy focuses on antineoplastics with low biodegradability and significant ecological risks, utilizing data from São Paulo, Brazil, to predict the mass of these drugs entering waterways and creating a prioritization index based on multiple risk factors.
- * Key prioritized antineoplastics identified include Paclitaxel and Cisplatin, highlighting the strategy's versatility for adapting to different contexts and improving drug environmental impact assessments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!